The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received conditional marketing approval from the European Commission for its liver ...